Comparative Efficacy of PD-1 Inhibitor-Based Neoadjuvant Chemoimmunotherapy Regimens for Resectable Stage II-IIIa NSCLC: A Real-World Retrospective Study.

Thorac Cancer · 2025 · PMC12234159 · PMID 40623866

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

a favorable trendno p-value reported

The camrelizumab group (HR: 0.218, 95% CI: 0.026–1.844, p = 0.162) showed a favorable trend, but the result was not statistically significant, likely due to small sample size and high censoring rate.

also in 907 other papers

a nonsignificant trendno p-value reported

Tislelizumab (HR: 0.167) and sintilimab (HR: 0.090) were associated with superior OS compared with pembrolizumab (reference); camrelizumab showed a nonsignificant trend.

also in 2,739 other papers

did not reach statistical significanceno p-value reported

Both tislelizumab and sintilimab were associated with significantly lower hazards of death than pembrolizumab, whereas the camrelizumab group showed a favorable trend that did not reach statistical significance, likely due to small sample size and high censoring rate.

also in 59,377 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.